The NZV930 program

About the target
CD73 is an ectoenzyme that plays a key role in the generation of extracellular adenosine, a critical modulator of the immune response. Inhibition of CD73 reduces levels of immunosuppressive adenosine in the tumor microenvironment, allowing key immune cells, including T cells, to attack the tumor.

About our antibody candidate
NZV930 is a fully human anti-CD73 antibody that has been shown in preclinical studies to inhibit CD73 enzymatic activity, reduce levels of adenosine and increase the proliferation of T cell receptor-stimulated CD4+ T cells. Additionally, preclinical studies have provided compelling evidence of anti-tumor activity when combining a CD73 inhibitor with a PD-1 inhibitor.

We have granted Novartis worldwide development and commercialization rights to NZV930 and a Phase I clinical trial was initiated in June 2018.

Clinical trial information
A first-in-human study of NZV930 is being led by Novartis which was granted a worldwide exclusive license to develop and commercialize NZV930 as part of its broad strategic collaboration with Surface. The Phase I study will evaluate the safety, tolerability and preliminary anti-tumor activity of NZV930 as a single agent and in combination with other cancer immunotherapies. The initial dose escalation portion of the trial will include patients with triple negative breast cancer, ovarian cancer, microsatellite stable colon cancer, pancreatic cancer, non-small cell lung cancer, and renal cell carcinoma. For more information about our clinical trials, visit www.clinicaltrials.gov.

Compassionate Use Statement
Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial.

Surface Oncology does not currently have an expanded access program or compassionate use program for any of our investigational products.

We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs provides the best path to meet our goal of providing therapeutics to patients with cancer.

We encourage you to speak with your physician about options that may be right for you.